News
KRRO
12.91
-2.64%
-0.35
Weekly Report: what happened at KRRO last week (0817-0821)?
Weekly Report · 6d ago
Korro Bio Moves KRRO-121 Into First Human Trials, Raising the Stakes in Rare Disease RNA Editing
TipRanks · 08/20 16:31
Korro Bio Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Dow Jones · 08/20 11:49
HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $15 Price Target
Benzinga · 08/20 11:39
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), CervoMed (CRVO) and Korro Bio (KRRO)
TipRanks · 08/20 10:30
Korro Bio Advances KRRO-121 Into First Human Trial
TipRanks · 08/19 20:31
Korro Bio Submits To Australian Alfred Health Human Ethics Committee To Start Phase 1/2 Clinical Study Of KRRO-121 To Treat Hyperammonemia In Patients With Urea Cycle Disorders
Benzinga · 08/19 20:11
Weekly Report: what happened at KRRO last week (0810-0814)?
Weekly Report · 08/17 09:33
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 08/14 15:05
Major Investor Quietly Boosts Stake in Korro Bio
TipRanks · 08/14 02:08
Weekly Report: what happened at KRRO last week (0803-0807)?
Weekly Report · 08/10 09:31
Analysts Offer Insights on Healthcare Companies: Corbus Pharmaceuticals (CRBP) and Korro Bio (KRRO)
TipRanks · 08/08 01:50
Buy Rating Reiterated on Strong Pipeline Progress and Clinical Catalysts; $21 Price Target Unchanged
TipRanks · 08/07 19:25
Piper Sandler Keeps Their Buy Rating on Korro Bio (KRRO)
TipRanks · 08/07 15:26
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Korro Bio (KRRO), Electrocore (ECOR) and BioLife Solutions (BLFS)
TipRanks · 08/07 13:20
Korro Bio Retains Buy Rating as Advancing RNA Editing Pipeline and Strong Cash Runway Support Unchanged $15 Price Target
TipRanks · 08/07 10:56
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Halozyme (HALO) and Resmed (RMD)
TipRanks · 08/07 09:30
Analyst Reaffirms Buy on Korro Bio, Citing Undervalued OPERA RNA Editing Platform and Multi-Billion-Dollar Pipeline Potential
TipRanks · 08/07 08:05
Analysts Have Conflicting Sentiments on These Healthcare Companies: Korro Bio (KRRO), Ardelyx (ARDX) and Kymera Therapeutics (KYMR)
TipRanks · 08/07 01:50
Korro Bio GAAP EPS of -$1.07, revenue of $1.5M
Seeking Alpha · 08/06 12:26
More
Webull provides a variety of real-time KRRO stock news. You can receive the latest news about Korro Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About KRRO
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.